Escitalopram
Drug10 milligrams administered each morning
Other names: Lexapro
NCT Number: NCT02175602
The purpose of this study is to assess the effect of Daclatasvir, Asunaprevir, and BMS-791325 on the pharmacokinetics of selective serotonin reuptake inhibitors.
Looking for future studies?
Notify Me25 year–55 year
All sexes
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
a) Signed written informed consent must be obtained from the subjects in accordance with requirements of the study center's IRB or IEC before the initiation of any protocol-required procedures.
a) Healthy subjects as determined by no clinically significant deviation from normal in medical history, psychiatric history, physical examination findings, vital sign measurements, 12-lead ECG measurements, physical measurements, and clinical laboratory test results.
Exclusion criteria
10 milligrams administered each morning
Other names: Lexapro
50 milligrams administered each morning
Other names: Zoloft
Fixed dose combination (daclatasvir [DCV] 30 milligrams, asunaprevir [ASV] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
75 milligrams single-agent film coated oral tablet administered twice daily
Time frame: Before dosing (0 hour) through 24 hours after SSRI administration on day 7 and day 29
Time frame: Before dosing (0 hour) through 12 hours after SSRI administration on day 22 and day 29
Time frame: Two to three months
Bristol-Myers Squibb
Industry
Effect of a Combination of Daclatasvir, Asunaprevir, and BMS-791325 on the Pharmacokinetics of Selective Serotonin Reuptake Inhibitors in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03601546
Blood-Borne Infections, Communicable Diseases
Nîmes, France
View Trial DetailsNCT02940496
Adenocarcinoma, BCLC Stage B Hepatocellular Carcinoma
Houston, Texas, United States
View Trial DetailsNCT02143401
Adenocarcinoma, Blood-Borne Infections
Scottsdale, Arizona, United States
View Trial DetailsNCT04042740
Blood-Borne Infections, Communicable Diseases
San Diego, California, United States
View Trial Details